1
|
Lorenzini B, Peltzer J, Goulinet S, Rival B, Lataillade JJ, Uzan G, Banzet S, Mauduit P. Producing vesicle-free cell culture additive for human cells extracellular vesicles manufacturing. J Control Release 2023; 355:501-514. [PMID: 36764527 DOI: 10.1016/j.jconrel.2023.01.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 01/22/2023] [Accepted: 01/29/2023] [Indexed: 02/12/2023]
Abstract
A new paradigm has emerged recently, which consists in shifting from cell therapy to a more flexible acellular "extracellular vesicle (EV) therapy" approach, thereby opening a new and promising field in nanomedicine. Important technical limitations have still to be addressed for the large-scale production of clinical-grade EV. Cells are cultured in media supplemented with human platelet lysate (hPL) (xenogenic-free) or GMP-grade fetal calf serum (FCS). However, these additives contain high amounts of EV that cannot be separated from cell-secreted -EV. Therefore, cells are generally maintained in additive-free medium during the EV secretion phase, however this can substantially limit their survival. In the present work, we developed a method to prepare vesicle-free hPL (EV-free hPL) or vesicle-free FCS (EV-free FCS) using tangential flow filtration (TFF). We show a very efficient EV depletion (>98%) for both pure hPL and FCS, with a highly conserved protein content. Culture medium containing our EV-free additives supported the survival of human bone marrow MSC (BM-MSC). MSC could survive at least 216 h, their conditioned medium being collected and changed every 72 h. Both the cell survival and the cumulative EV production were substantially higher than in the starving conditions classically used for EV production. In EV-free hPL containing medium, we show that purified EV kept their morphologic and molecular characteristics throughout the production. Finally, we tested our additives with 3 other cell types, human primary Endothelial Colony Forming Cells (ECFC) and two non-adherent human cell lines, Jurkat and THP-1. We confirmed that both EV-free hPL and FCS were able to maintain cell survival and EV production for at least 216 h. Our method provides therefore a new option to help producing large amounts of EV from virtually any mammalian cells, particularly those that do not tolerate starvation. This method can apply to any animal serum for research and development purpose. Moreover, EV-free hPL is clinical-grade compatible and allows preparing xenobiotic-free media for massive therapeutic EV production in both 2D (cell plates) and 3D (bioreactor) setting.
Collapse
Affiliation(s)
- Bileyle Lorenzini
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France
| | - Juliette Peltzer
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France; Institut de Recherche Biomédicale des Armées, Centre de Transfusion Sanguine des Armées, 1 rue Lt Raoul Batany, 92140 Clamart, France
| | - Sylvie Goulinet
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France
| | - Bastien Rival
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France; Institut de Recherche Biomédicale des Armées, Centre de Transfusion Sanguine des Armées, 1 rue Lt Raoul Batany, 92140 Clamart, France
| | | | - Georges Uzan
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France
| | - Sébastien Banzet
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France; Institut de Recherche Biomédicale des Armées, Centre de Transfusion Sanguine des Armées, 1 rue Lt Raoul Batany, 92140 Clamart, France; Centre de Transfusion Sanguine des Armées, 1 rue Lt Raoul Batany, 92140 Clamart, France.
| | - Philippe Mauduit
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France.
| |
Collapse
|